Drug intelligence / Profile preview

UNI50002

Development stage: Preclinical
Lead developer: UNION therapeutics
Modality: Small Molecules
Administration: Topical

Overview

**UNI50002** is a topical formulation of **orismilast**, a non-steroidal, small-molecule phosphodiesterase 4 inhibitor being developed by **UNION Therapeutics** for **atopic dermatitis**. Orismilast is described as a next-generation PDE4 inhibitor with broad anti-inflammatory activity, and UNI50002 is intended to deliver local PDE4 inhibition through topical administration for inflammatory skin disease. The program is part of UNION Therapeutics' orismilast franchise, alongside oral orismilast, with UNI50002 specifically positioned for atopic dermatitis.

Other names: topical orismilast

Targets

PDE4B (3',5'-cyclic-AMP phosphodiesterase 4B)PDE4D (Phosphodiesterase 4D)

Beyond the preview

Go deeper on UNI50002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UNI50002.

Explore the full profile